Aspira Women's Health Inc. (AWH)
USD 0.08
(0.0%)
USD 0.08
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.26 Million USD | -63.96% |
| 2022 | 17.37 Million USD | -57.71% |
| 2021 | 41.07 Million USD | 109.53% |
| 2020 | 19.6 Million USD | 41.78% |
| 2019 | 13.82 Million USD | 21.21% |
| 2018 | 11.4 Million USD | 52.17% |
| 2017 | 7.49 Million USD | -6.51% |
| 2016 | 8.01 Million USD | -61.74% |
| 2015 | 20.96 Million USD | -13.3% |
| 2014 | 24.17 Million USD | -21.1% |
| 2013 | 30.64 Million USD | 254.88% |
| 2012 | 8.63 Million USD | -62.64% |
| 2011 | 23.11 Million USD | -3.84% |
| 2010 | 24.03 Million USD | 421.48% |
| 2009 | 4.6 Million USD | 19.47% |
| 2008 | 3.85 Million USD | -83.96% |
| 2007 | 24.05 Million USD | 4.51% |
| 2006 | 23.01 Million USD | -56.42% |
| 2005 | 52.81 Million USD | -29.0% |
| 2004 | 74.37 Million USD | -27.1% |
| 2003 | 102.02 Million USD | 16.45% |
| 2002 | 87.61 Million USD | -17.98% |
| 2001 | 106.81 Million USD | -10.2% |
| 2000 | 118.94 Million USD | 1637.99% |
| 1999 | 6.84 Million USD | -38.59% |
| 1998 | 11.14 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.16 Million USD | 14.4% |
| 2024 Q2 | 3.96 Million USD | -44.71% |
| 2023 Q1 | 11.49 Million USD | -33.83% |
| 2023 Q2 | 7.72 Million USD | -32.85% |
| 2023 Q3 | 8.66 Million USD | 12.2% |
| 2023 Q4 | 6.26 Million USD | -27.71% |
| 2023 FY | 6.26 Million USD | -63.96% |
| 2022 Q4 | 17.37 Million USD | -27.44% |
| 2022 FY | 17.37 Million USD | -57.71% |
| 2022 Q2 | 24.01 Million USD | -22.18% |
| 2022 Q1 | 30.86 Million USD | -24.87% |
| 2022 Q3 | 23.94 Million USD | -0.31% |
| 2021 Q3 | 48.04 Million USD | -13.94% |
| 2021 Q4 | 41.07 Million USD | -14.5% |
| 2021 FY | 41.07 Million USD | 109.53% |
| 2021 Q1 | 62.29 Million USD | 217.76% |
| 2021 Q2 | 55.82 Million USD | -10.38% |
| 2020 FY | 19.6 Million USD | 41.78% |
| 2020 Q1 | 10.35 Million USD | -25.13% |
| 2020 Q2 | 13.09 Million USD | 26.45% |
| 2020 Q3 | 21.26 Million USD | 62.44% |
| 2020 Q4 | 19.6 Million USD | -7.81% |
| 2019 FY | 13.82 Million USD | 21.21% |
| 2019 Q2 | 18.15 Million USD | 119.92% |
| 2019 Q1 | 8.25 Million USD | -27.65% |
| 2019 Q3 | 16.53 Million USD | -8.92% |
| 2019 Q4 | 13.82 Million USD | -16.36% |
| 2018 Q4 | 11.4 Million USD | -15.33% |
| 2018 Q1 | 5.44 Million USD | -27.34% |
| 2018 Q2 | 16.12 Million USD | 195.96% |
| 2018 FY | 11.4 Million USD | 52.17% |
| 2018 Q3 | 13.47 Million USD | -16.42% |
| 2017 Q3 | 9.67 Million USD | 18.41% |
| 2017 Q2 | 8.17 Million USD | -21.73% |
| 2017 FY | 7.49 Million USD | -6.51% |
| 2017 Q4 | 7.49 Million USD | -22.54% |
| 2017 Q1 | 10.44 Million USD | 30.22% |
| 2016 FY | 8.01 Million USD | -61.74% |
| 2016 Q1 | 15.87 Million USD | -24.27% |
| 2016 Q2 | 13.89 Million USD | -12.43% |
| 2016 Q3 | 10.68 Million USD | -23.15% |
| 2016 Q4 | 8.01 Million USD | -24.93% |
| 2015 Q4 | 20.96 Million USD | -17.44% |
| 2015 FY | 20.96 Million USD | -13.3% |
| 2015 Q3 | 25.38 Million USD | 105.83% |
| 2015 Q2 | 12.33 Million USD | -33.95% |
| 2015 Q1 | 18.67 Million USD | -22.75% |
| 2014 Q1 | 27.27 Million USD | -10.99% |
| 2014 Q3 | 18.4 Million USD | -21.71% |
| 2014 FY | 24.17 Million USD | -21.1% |
| 2014 Q2 | 23.51 Million USD | -13.79% |
| 2014 Q4 | 24.17 Million USD | 31.33% |
| 2013 Q2 | 16.89 Million USD | 159.62% |
| 2013 Q3 | 15.08 Million USD | -10.7% |
| 2013 Q4 | 30.64 Million USD | 103.13% |
| 2013 FY | 30.64 Million USD | 254.88% |
| 2013 Q1 | 6.5 Million USD | -24.65% |
| 2012 Q3 | 16.88 Million USD | -10.76% |
| 2012 Q2 | 18.91 Million USD | -7.9% |
| 2012 Q1 | 20.54 Million USD | -11.12% |
| 2012 Q4 | 8.63 Million USD | -48.86% |
| 2012 FY | 8.63 Million USD | -62.64% |
| 2011 FY | 23.11 Million USD | -3.84% |
| 2011 Q1 | 40.9 Million USD | 70.2% |
| 2011 Q3 | 28.04 Million USD | -24.37% |
| 2011 Q4 | 23.11 Million USD | -17.6% |
| 2011 Q2 | 37.08 Million USD | -9.34% |
| 2010 Q2 | 29.89 Million USD | -22.81% |
| 2010 FY | 24.03 Million USD | 421.48% |
| 2010 Q1 | 38.73 Million USD | 740.36% |
| 2010 Q4 | 24.03 Million USD | -8.84% |
| 2010 Q3 | 26.36 Million USD | -11.81% |
| 2009 Q4 | 4.6 Million USD | 77.27% |
| 2009 Q1 | 2.02 Million USD | -47.56% |
| 2009 FY | 4.6 Million USD | 19.47% |
| 2009 Q3 | 2.6 Million USD | 75.08% |
| 2009 Q2 | 1.48 Million USD | -26.59% |
| 2008 Q3 | 7.15 Million USD | -43.63% |
| 2008 FY | 3.85 Million USD | -83.96% |
| 2008 Q1 | 17.55 Million USD | -27.02% |
| 2008 Q2 | 12.68 Million USD | -27.75% |
| 2008 Q4 | 3.85 Million USD | -46.04% |
| 2007 FY | 24.05 Million USD | 4.51% |
| 2007 Q1 | 18.3 Million USD | -20.48% |
| 2007 Q2 | 13.15 Million USD | -28.12% |
| 2007 Q3 | 26.86 Million USD | 104.23% |
| 2007 Q4 | 24.05 Million USD | -10.47% |
| 2006 Q3 | 34.64 Million USD | -15.41% |
| 2006 FY | 23.01 Million USD | -56.42% |
| 2006 Q1 | 46.74 Million USD | -11.49% |
| 2006 Q2 | 40.95 Million USD | -12.39% |
| 2006 Q4 | 23.01 Million USD | -33.56% |
| 2005 Q2 | 53.78 Million USD | -13.68% |
| 2005 Q1 | 62.31 Million USD | -16.22% |
| 2005 Q3 | 59.6 Million USD | 10.83% |
| 2005 Q4 | 52.81 Million USD | -11.4% |
| 2005 FY | 52.81 Million USD | -29.0% |
| 2004 Q2 | 81.17 Million USD | -13.93% |
| 2004 FY | 74.37 Million USD | -27.1% |
| 2004 Q4 | 74.37 Million USD | 6.37% |
| 2004 Q1 | 94.31 Million USD | -7.56% |
| 2004 Q3 | 69.92 Million USD | -13.86% |
| 2003 Q2 | 76.94 Million USD | -4.42% |
| 2003 Q3 | 103.66 Million USD | 34.72% |
| 2003 Q4 | 102.02 Million USD | -1.58% |
| 2003 Q1 | 80.51 Million USD | -8.11% |
| 2003 FY | 102.02 Million USD | 16.45% |
| 2002 Q3 | 90.74 Million USD | -5.7% |
| 2002 Q1 | 99.75 Million USD | -6.61% |
| 2002 FY | 87.61 Million USD | -17.98% |
| 2002 Q4 | 87.61 Million USD | -3.45% |
| 2002 Q2 | 96.23 Million USD | -3.52% |
| 2001 Q4 | 106.81 Million USD | -3.54% |
| 2001 Q3 | 110.74 Million USD | -0.39% |
| 2001 Q2 | 111.17 Million USD | -3.49% |
| 2001 FY | 106.81 Million USD | -10.2% |
| 2001 Q1 | 115.19 Million USD | -3.15% |
| 2000 Q4 | 118.94 Million USD | 8.67% |
| 2000 Q3 | 109.45 Million USD | 0.0% |
| 2000 FY | 118.94 Million USD | 1637.99% |
| 1999 FY | 6.84 Million USD | -38.59% |
| 1998 FY | 11.14 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 96.828% |
| Biodesix, Inc. | 99.09 Million USD | 93.681% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | 23.834% |
| Castle Biosciences, Inc. | 477.81 Million USD | 98.689% |
| DarioHealth Corp. | 96.38 Million USD | 93.503% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.903% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.808% |
| Illumina, Inc. | 10.11 Billion USD | 99.938% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | 54.554% |
| iSpecimen Inc. | 15.81 Million USD | 60.415% |
| Standard BioTools Inc. | 323.06 Million USD | 98.062% |
| 23andMe Holding Co. | 395.16 Million USD | 98.415% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 99.622% |
| NeoGenomics, Inc. | 1.68 Billion USD | 99.628% |
| Inotiv, Inc. | 856.53 Million USD | 99.269% |
| Psychemedics Corporation | 13.27 Million USD | 52.811% |
| Prenetics Global Limited | 254.17 Million USD | 97.536% |
| Precipio, Inc. | 18.1 Million USD | 65.405% |
| RadNet, Inc. | 2.88 Billion USD | 99.783% |
| Sotera Health Company | 3.13 Billion USD | 99.8% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 92.8% |
| Exagen Inc. | 56.94 Million USD | 89.003% |
| Natera, Inc. | 1.45 Billion USD | 99.57% |
| Neogen Corporation | 4.58 Billion USD | 99.863% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 99.478% |
| ICON Public Limited Company | 16.98 Billion USD | 99.963% |
| Bionano Genomics, Inc. | 214.4 Million USD | 97.079% |
| CareDx, Inc | 484.61 Million USD | 98.708% |
| Check-Cap Ltd. | 25.01 Million USD | 74.969% |
| Twist Bioscience Corporation | 776.4 Million USD | 99.193% |
| Guardant Health, Inc. | 1.78 Billion USD | 99.649% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | 45.069% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 99.508% |
| Sera Prognostics, Inc. | 95.44 Million USD | 93.439% |
| OPKO Health, Inc. | 2.01 Billion USD | 99.689% |
| Personalis, Inc. | 225.09 Million USD | 97.218% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | 54.13% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 92.8% |
| MDxHealth SA | 129.13 Million USD | 95.151% |
| Prenetics Global Limited | 254.17 Million USD | 97.536% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | 7.287% |
| Mainz Biomed B.V. | 15.4 Million USD | 59.361% |
| Trinity Biotech plc | 59.43 Million USD | 89.464% |
| Neuronetics, Inc. | 115.83 Million USD | 94.594% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | 23.834% |